Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Fluconazole 50 mg Capsules in Healthy Adults
NCT03821480Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluconazole in fungal infection (2 arms), sponsored by Pfizer. Primary endpoints: Area Under Curve [AUC]last at 96 hours and Maximum Plasma Concentration at 96 hours. Started Jan 2019; status: completed.
02
Drugs
fluconazole
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT03821480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821480.